EP0628056A4 - Immunoglobuline humaine dirigee pour la prevention et le traitement de staphylococcies. - Google Patents

Immunoglobuline humaine dirigee pour la prevention et le traitement de staphylococcies.

Info

Publication number
EP0628056A4
EP0628056A4 EP93901435A EP93901435A EP0628056A4 EP 0628056 A4 EP0628056 A4 EP 0628056A4 EP 93901435 A EP93901435 A EP 93901435A EP 93901435 A EP93901435 A EP 93901435A EP 0628056 A4 EP0628056 A4 EP 0628056A4
Authority
EP
European Patent Office
Prior art keywords
prevention
treatment
human immune
immune globulin
staphylococcal infections
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP93901435A
Other languages
German (de)
English (en)
Other versions
EP0628056A1 (fr
Inventor
Gerald W Fischer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Henry M Jackson Foundation for Advancedment of Military Medicine Inc
Original Assignee
Henry M Jackson Foundation for Advancedment of Military Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henry M Jackson Foundation for Advancedment of Military Medicine Inc filed Critical Henry M Jackson Foundation for Advancedment of Military Medicine Inc
Publication of EP0628056A1 publication Critical patent/EP0628056A1/fr
Publication of EP0628056A4 publication Critical patent/EP0628056A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/305—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F)
    • G01N2333/31—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F) from Staphylococcus (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP93901435A 1992-02-25 1992-11-09 Immunoglobuline humaine dirigee pour la prevention et le traitement de staphylococcies. Withdrawn EP0628056A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80431792A 1992-02-25 1992-02-25
US804317 1992-02-25
PCT/US1992/009830 WO1993017044A1 (fr) 1992-02-25 1992-11-09 Immunoglobuline humaine dirigee pour la prevention et le traitement de staphylococcies

Publications (2)

Publication Number Publication Date
EP0628056A1 EP0628056A1 (fr) 1994-12-14
EP0628056A4 true EP0628056A4 (fr) 1997-03-05

Family

ID=25188685

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93901435A Withdrawn EP0628056A4 (fr) 1992-02-25 1992-11-09 Immunoglobuline humaine dirigee pour la prevention et le traitement de staphylococcies.

Country Status (5)

Country Link
EP (1) EP0628056A4 (fr)
JP (1) JPH08504167A (fr)
AU (1) AU673508B2 (fr)
CA (1) CA2117480A1 (fr)
WO (1) WO1993017044A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE197506T1 (de) * 1992-03-19 2000-11-11 Jackson H M Found Military Med Breitreaktive opsonische antikörper die mit gemeinsamen antigenen von staphylococcus reagieren
US6933366B2 (en) 1996-12-27 2005-08-23 Tripep Ab Specificity exchangers that redirect antibodies to bacterial adhesion receptors
US6660842B1 (en) 1994-04-28 2003-12-09 Tripep Ab Ligand/receptor specificity exchangers that redirect antibodies to receptors on a pathogen
JPH0840932A (ja) 1994-07-29 1996-02-13 Kitasato Inst:The スタフイロコッカス属菌感染症の予防ワクチン及び治療用抗体並びにそれの製造法
US6610293B1 (en) 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
US7250494B2 (en) 1998-06-15 2007-07-31 Biosynexus Incorporated Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria
US6692739B1 (en) 1998-08-31 2004-02-17 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation
US7318926B2 (en) 2003-02-06 2008-01-15 Tripep Ab Glycosylated specificity exchangers
US7335359B2 (en) 2003-02-06 2008-02-26 Tripep Ab Glycosylated specificity exchangers
US20090214584A1 (en) * 2005-05-31 2009-08-27 Biostapro Ab Characterization of novel lpxtg-containing proteins of staphylococcus epidermidis
EA016268B1 (ru) * 2009-05-12 2012-03-30 Государственное Учреждение ''Республиканский Научно-Практический Центр Трансфузиологии И Медицинских Биотехнологий'' Способ получения антистафилококковой плазмы крови
FR2989589A1 (fr) * 2012-04-20 2013-10-25 Univ Paris Curie Prevention et traitement des infections non virales chez des individus traites par des immunosuppresseurs

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1499035A (en) * 1975-04-10 1978-01-25 Ts Nii Gematologii I Perelivan Antistaphylococcus human immune globulin and method of preparing same
JPS5452794A (en) * 1977-09-30 1979-04-25 Kousaku Yoshida Extracting of polysacchride from capusle containing epidermis staphylococus

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
C.P. TIMMERMAN ET AL.: "Characterisation and functional aspects of monoclonal antibodies specific for surface proteins of coagulase-negative staphylococci", THE JOURNAL OF MEDICAL MICROBIOLOGY, vol. 35, 13 August 1991 (1991-08-13), pages 65 - 71, XP000613626 *
GERALD W. FISCHER ET AL.: "Directed immune globulin enhances survival in an intralipid induced neonatal model of lethal Staphylococcus epidermidis sepsis", PEDIATRIC RESEARCH, vol. 29, no. 4, April 1991 (1991-04-01), pages 281A, XP000613632 *
See also references of WO9317044A1 *
THEODORE J. CIESLAK ET AL.: "Post-immunization antibodies to S. epidermidis are broadly reactive and opsonic", PEDIATRIC RESEARCH, vol. 31, no. 4, April 1992 (1992-04-01), pages 275A, XP000613625 *
VAN OSS, CAREL J. ET AL: "Immunoglobulins as aspecific opsonins. III. Opsonizing power of fragments of polyclonal and monoclonal immunoglobulin G", RES J. RETICULOENDOTHEL. SOC. (1973), 13(3), 221-30 CODEN: RESJAS, 1973, XP000613681 *

Also Published As

Publication number Publication date
JPH08504167A (ja) 1996-05-07
AU3271893A (en) 1993-09-13
EP0628056A1 (fr) 1994-12-14
CA2117480A1 (fr) 1993-09-02
WO1993017044A1 (fr) 1993-09-02
AU673508B2 (en) 1996-11-14

Similar Documents

Publication Publication Date Title
ZA926986B (en) Exhaust treatment system
GB9115276D0 (en) Skin treatment system
TJ384B (en) Microfluidized compostion for induction of specific cytotoxic t-lymphocyte immune response and its using for disease treatment.
EP0628056A4 (fr) Immunoglobuline humaine dirigee pour la prevention et le traitement de staphylococcies.
EP0559791A4 (en) Treatment of topical infections
GB9226683D0 (en) Skin treatment system
HK1011411A1 (en) Human body detection system
AU3328693A (en) Treatment of fungal infections
AU2807492A (en) Use of misoprostol for the treatment of allergy
SG72610A1 (en) Therapeutic agent from my cobacterium vaccae and its use against hiv infection
EP0577023A3 (en) Angiotensin-ii receptor-antagonists for the treatment of arrhythmices
GB9222260D0 (en) Skin treatment
ZA931063B (en) Treatment of glaucoma.
IL113191A0 (en) Treatment of h. pylori infections
EP0679083A4 (fr) Prevention et traitement de la septicemie.
GB9217124D0 (en) Medical treatment
EP0655919A4 (fr) Traitement d'infections virales chez l'homme.
ZA93348B (en) Treatment of liquids.
ZA941244B (en) Selective treatment of enteroviral-caused infections in humans
GB9218773D0 (en) Skin treatment
HUT68145A (en) Procedure for the treatment and shaping of hair
EP0502470A3 (en) Compounds for the treatment of inflammation and allergy
GB2270260B (en) Lactide copolymers for topical treatment of the skin
GB9310882D0 (en) Allergic treatment
KR940002718U (ko) 치질예방 및 치료기

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19940824

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF

RIN1 Information on inventor provided before grant (corrected)

Inventor name: FISCHER, GERALD W.

RHK1 Main classification (correction)

Ipc: C12P 21/08

A4 Supplementary search report drawn up and despatched

Effective date: 19970117

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL SE

17Q First examination report despatched

Effective date: 19980917

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19991201